Todd Wallach was a founder of Acuity Pharmaceuticals, Inc (now Opko Health) and Chief Financial Officer of Aton Pharma, Inc. James Patterson joins Biopticon from a long history in sales and marketing with Beckman Coulter, most recently as Director of Sales Operations. Dale Pfost has been a founder of several biotechnology companies including Orchid BioSciences, Acuity Pharmaceuticals, and the company that produced the Biomek laboratory robot. Most recently he had been the CEO of Receptor BioLogix.

"I am proud to have both Todd and James join our company. We have assembled a strong team of biotechnology leaders and professionals with significant experience to rapidly move our company forward," said Dr. Cem Girit, Biopticon's Founder and President. "With the expertise of this team we are well positioned to advance our first product to market and become an industry leader in pre-clinical imaging technologies," said Dale Pfost.

"We are pleased with the excitement created by the introduction of the Tumor Management System at AACR," said James Patterson, Biopticon's Vice President of Sales and Marketing. "This product greatly improves the quality of the data from preclinical xenograft studies and data analysis and reporting is easy. Customer evaluations have demonstrated that typical standard error when using calipers is reduced three-fold with the TumorImagerTM. Better data can be achieved uniformly across studies and serve as a more reliable basis for critical decision-making and greater confidence. Less than four seconds are required for a measurement and the data is automatically stored in the network database, greatly simplifying and accelerating the lab process. We believe that our system will become the gold standard that will render the age of mechanical caliper-based measurements as dated."

 “This patent recognizes the uniqueness of the technology incorporated in the recently launched TumorImager™ System”, said Dr. Cem Girit, Founder and President of Biopticon.  “This system was designed to improve the efficiency of data collection, accuracy and repeatability while simplifying and automating the process of conducting preclinical oncology drug studies using xenograft tumors on nude mice.  Since the TumorManager™ automatically captures data from the scanner, balances and RFID readers, transcription errors are eliminated and technician time is reduced when compared to current manually intensive methods using calipers.”

In a recent paper published in Comparative Medicine (Vol. 58, No. 3, June 2008), TumorImager™ demonstrated improved volume measurement accuracy regardless of the shape or presence of necrotic areas on the tumor, when compared to manual measurement via calipers.  TumorImager™ data was also found to be significantly less dependent on the technique used by the individual technician taking the measurements.